Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Protein Kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13.

Bentin Toaldo C, Alexi X, Beelen K, Kok M, Hauptmann M, Jansen M, Berns E, Neefjes J, Linn S, Michalides R, Zwart W.

BMC Cancer. 2015 Aug 14;15:588. doi: 10.1186/s12885-015-1591-4.

2.

Interaction of 14-3-3 proteins with the estrogen receptor alpha F domain provides a drug target interface.

De Vries-van Leeuwen IJ, da Costa Pereira D, Flach KD, Piersma SR, Haase C, Bier D, Yalcin Z, Michalides R, Feenstra KA, Jiménez CR, de Greef TF, Brunsveld L, Ottmann C, Zwart W, de Boer AH.

Proc Natl Acad Sci U S A. 2013 May 28;110(22):8894-9. doi: 10.1073/pnas.1220809110. Epub 2013 May 15.

3.

PKA phosphorylation redirects ERα to promoters of a unique gene set to induce tamoxifen resistance.

de Leeuw R, Flach K, Bentin Toaldo C, Alexi X, Canisius S, Neefjes J, Michalides R, Zwart W.

Oncogene. 2013 Jul 25;32(30):3543-51. doi: 10.1038/onc.2012.361. Epub 2012 Aug 20.

PMID:
22907427
4.

Serine-305 phosphorylation modulates estrogen receptor alpha binding to a coregulator peptide array, with potential application in predicting responses to tamoxifen.

Houtman R, de Leeuw R, Rondaij M, Melchers D, Verwoerd D, Ruijtenbeek R, Martens JW, Neefjes J, Michalides R.

Mol Cancer Ther. 2012 Apr;11(4):805-16. doi: 10.1158/1535-7163.MCT-11-0855. Epub 2012 Feb 7.

5.

A role for estrogen receptor phosphorylation in the resistance to tamoxifen.

de Leeuw R, Neefjes J, Michalides R.

Int J Breast Cancer. 2011;2011:232435. doi: 10.4061/2011/232435. Epub 2011 Jul 12.

6.

The hinge region of the human estrogen receptor determines functional synergy between AF-1 and AF-2 in the quantitative response to estradiol and tamoxifen.

Zwart W, de Leeuw R, Rondaij M, Neefjes J, Mancini MA, Michalides R.

J Cell Sci. 2010 Apr 15;123(Pt 8):1253-61. doi: 10.1242/jcs.061135. Epub 2010 Mar 23.

7.

PKA-induced phosphorylation of ERα at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer.

Kok M, Zwart W, Holm C, Fles R, Hauptmann M, Van't Veer LJ, Wessels LF, Neefjes J, Stål O, Linn SC, Landberg G, Michalides R.

Breast Cancer Res Treat. 2011 Jan;125(1):1-12. doi: 10.1007/s10549-010-0798-y. Epub 2010 Mar 9.

PMID:
20213082
8.

Estrogen receptor-alpha phosphorylation at serine-118 and tamoxifen response in breast cancer.

Kok M, Holm-Wigerup C, Hauptmann M, Michalides R, Stål O, Linn S, Landberg G.

J Natl Cancer Inst. 2009 Dec 16;101(24):1725-9. doi: 10.1093/jnci/djp412. Erratum in: J Natl Cancer Inst. 2010 Feb 3;102(3):208.

PMID:
19940281
9.

Perturbation of estrogen receptor alpha localization with synthetic nona-arginine LXXLL-peptide coactivator binding inhibitors.

Carraz M, Zwart W, Phan T, Michalides R, Brunsveld L.

Chem Biol. 2009 Jul 31;16(7):702-11. doi: 10.1016/j.chembiol.2009.06.009.

10.

Resistance to antiestrogen arzoxifene is mediated by overexpression of cyclin D1.

Zwart W, Rondaij M, Jalink K, Sharp ZD, Mancini MA, Neefjes J, Michalides R.

Mol Endocrinol. 2009 Sep;23(9):1335-45. doi: 10.1210/me.2008-0268. Epub 2009 May 28.

11.

Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer.

Holm C, Kok M, Michalides R, Fles R, Koornstra RH, Wesseling J, Hauptmann M, Neefjes J, Peterse JL, Stål O, Landberg G, Linn SC.

J Pathol. 2009 Feb;217(3):372-9. doi: 10.1002/path.2455.

PMID:
18991335
12.

PKA-induced resistance to tamoxifen is associated with an altered orientation of ERalpha towards co-activator SRC-1.

Zwart W, Griekspoor A, Berno V, Lakeman K, Jalink K, Mancini M, Neefjes J, Michalides R.

EMBO J. 2007 Aug 8;26(15):3534-44. Epub 2007 Jul 12.

13.

Classification of anti-estrogens according to intramolecular FRET effects on phospho-mutants of estrogen receptor alpha.

Zwart W, Griekspoor A, Rondaij M, Verwoerd D, Neefjes J, Michalides R.

Mol Cancer Ther. 2007 May;6(5):1526-33.

14.

Visualizing the action of steroid hormone receptors in living cells.

Griekspoor A, Zwart W, Neefjes J, Michalides R.

Nucl Recept Signal. 2007 Mar 9;5:e003. Review.

15.

Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer.

Michalides R, Griekspoor A, Balkenende A, Verwoerd D, Janssen L, Jalink K, Floore A, Velds A, van't Veer L, Neefjes J.

Cancer Cell. 2004 Jun;5(6):597-605.

16.

Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells.

Bindels EM, Lallemand F, Balkenende A, Verwoerd D, Michalides R.

Oncogene. 2002 Nov 21;21(53):8158-65.

17.

Cell cycle regulators: role in etiology, prognosis and treatment in cancer.

Michalides R.

Ann Oncol. 2002;13 Suppl 4:39. Review. No abstract available.

PMID:
12401664
18.

Constitutive active GTPases Rac and Cdc42 are associated with endoreplication in PAE cells.

Muris DF, Verschoor T, Divecha N, Michalides RJ.

Eur J Cancer. 2002 Sep;38(13):1775-82.

PMID:
12175695
19.

Overexpression of cyclin D1 enhances taxol induced mitotic death in MCF7 cells.

Michalides R, Tiemessen M, Verschoor T, Balkenende A, Coco-Martin J.

Breast Cancer Res Treat. 2002 Jul;74(1):55-63.

PMID:
12150453
20.

Defects in G1-S cell cycle control in head and neck cancer: a review.

Michalides RJ, van de Brekel M, Balm F.

Head Neck. 2002 Jul;24(7):694-704. Review.

PMID:
12112544
21.

Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment.

Michalides R, van Tinteren H, Balkenende A, Vermorken JB, Benraadt J, Huldij J, van Diest P.

Br J Cancer. 2002 Feb 1;86(3):402-8.

22.

Inhibition of human breast cancer cell growth by blockade of the mevalonate-protein prenylation pathway is not prevented by overexpression of cyclin D1.

Germano D, Pacilio C, Cancemi M, Cicatiello L, Altucci L, Petrizzi VB, Sperandio C, Salzano S, Michalides RJ, Taya Y, Bresciani F, Weisz A.

Breast Cancer Res Treat. 2001 May;67(1):23-33.

PMID:
11518463
23.

Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade.

Mommers EC, Leonhart AM, Falix F, Michalides R, Meijer CJ, Baak JP, Diest PJ.

J Pathol. 2001 Jul;194(3):327-33.

PMID:
11439365
24.

p27(kip1) expression in breast carcinomas: an immunohistochemical study on 512 patients with long-term follow-up.

Barbareschi M, van Tinteren H, Mauri FA, Veronese S, Peterse H, Maisonneuve P, Caffo O, Scaioli M, Doglioni C, Galligioni E, Dalla Palma P, Michalides R.

Int J Cancer. 2000 May 20;89(3):236-41.

25.

Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer.

Michalides RJ.

J Clin Pathol. 1999 Aug;52(8):555-68. Review. No abstract available.

26.
28.

Cyclin D1 overexpression enhances radiation-induced apoptosis and radiosensitivity in a breast tumor cell line.

Coco Martin JM, Balkenende A, Verschoor T, Lallemand F, Michalides R.

Cancer Res. 1999 Mar 1;59(5):1134-40.

29.

Characterization of the EMS1 gene and its product, human Cortactin.

Schuuring E, van Damme H, Schuuring-Scholtes E, Verhoeven E, Michalides R, Geelen E, de Boer C, Brok H, van Buuren V, Kluin P.

Cell Adhes Commun. 1998;6(2-3):185-209.

PMID:
9823470
30.

Comparative analysis of p53 mutations in bladder washings and histologic specimens.

Vet JA, Hessels D, Marras SA, van de Kaa CA, van der Poel HG, Michalides RJ, Debruyne FM, Schalken JA.

Am J Clin Pathol. 1998 Nov;110(5):647-52.

PMID:
9802351
31.

Neural cell adhesion molecules (NCAM) and NCAM-PSA expression in neuroendocrine lung tumors.

Lantuejoul S, Moro D, Michalides RJ, Brambilla C, Brambilla E.

Am J Surg Pathol. 1998 Oct;22(10):1267-76.

PMID:
9777989
32.

Correlation of cyclin D1 and Rb gene expression with apoptosis in invasive breast cancer.

de Jong JS, van Diest PJ, Michalides RJ, van der Valk P, Meijer CJ, Baak JP.

Mol Pathol. 1998 Feb;51(1):30-4.

33.

Constitutive overexpression of cyclin D1 does not prevent inhibition of hormone-responsive human breast cancer cell growth by antiestrogens.

Pacilio C, Germano D, Addeo R, Altucci L, Petrizzi VB, Cancemi M, Cicatiello L, Salzano S, Lallemand F, Michalides RJ, Bresciani F, Weisz A.

Cancer Res. 1998 Mar 1;58(5):871-6.

34.

Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck.

Michalides RJ, van Veelen NM, Kristel PM, Hart AA, Loftus BM, Hilgers FJ, Balm AJ.

Arch Otolaryngol Head Neck Surg. 1997 May;123(5):497-502.

PMID:
9158396
35.

CDK-independent activation of estrogen receptor by cyclin D1.

Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R, Michalides RJ.

Cell. 1997 Feb 7;88(3):405-15.

36.

Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value.

van Diest PJ, Michalides RJ, Jannink L, van der Valk P, Peterse HL, de Jong JS, Meijer CJ, Baak JP.

Am J Pathol. 1997 Feb;150(2):705-11.

37.

Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression.

Akervall JA, Michalides RJ, Mineta H, Balm A, Borg A, Dictor MR, Jin Y, Loftus B, Mertens F, Wennerberg JP.

Cancer. 1997 Jan 15;79(2):380-9.

PMID:
9010112
38.

The prognostic value of NCAM, p53 and cyclin D1 in resected non-small cell lung cancer.

Kwa HB, Michalides RJ, Dijkman JH, Mooi WJ.

Lung Cancer. 1996 Jun;14(2-3):207-17.

PMID:
8794404
39.

Cyclin D1 triggers autonomous growth of breast cancer cells by governing cell cycle exit.

Zwijsen RM, Klompmaker R, Wientjens EB, Kristel PM, van der Burg B, Michalides RJ.

Mol Cell Biol. 1996 Jun;16(6):2554-60.

40.

A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer.

Michalides R, Hageman P, van Tinteren H, Houben L, Wientjens E, Klompmaker R, Peterse J.

Br J Cancer. 1996 Mar;73(6):728-34.

41.
42.

Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck.

Michalides R, van Veelen N, Hart A, Loftus B, Wientjens E, Balm A.

Cancer Res. 1995 Mar 1;55(5):975-8.

43.
44.

NCAM and lung cancer.

Michalides R, Kwa B, Springall D, van Zandwijk N, Koopman J, Hilkens J, Mooi W.

Int J Cancer Suppl. 1994;8:34-7.

PMID:
8194895
45.

Amplification of the 11q13 region in human carcinoma cell lines: a mechanistic view.

Roelofs H, Schuuring E, Wiegant J, Michalides R, Giphart-Gassler M.

Genes Chromosomes Cancer. 1993 Jun;7(2):74-84.

PMID:
7687456
47.

Amplified region of chromosome band 11q13 in breast and squamous cell carcinomas encompasses three CpG islands telomeric of FGF3, including the expressed gene EMS1.

Brookes S, Lammie GA, Schuuring E, de Boer C, Michalides R, Dickson C, Peters G.

Genes Chromosomes Cancer. 1993 Apr;6(4):222-31.

PMID:
7685625
48.

Alternative splicing of neural-cell-adhesion molecule mRNA in human small-cell lung-cancer cell line H69.

Moolenaar CE, Pieneman C, Walsh FS, Mooi WJ, Michalides RJ.

Int J Cancer. 1992 May 8;51(2):238-43.

PMID:
1314782
49.

The VASE exon downregulates the neurite growth-promoting activity of NCAM 140.

Doherty P, Moolenaar CE, Ashton SV, Michalides RJ, Walsh FS.

Nature. 1992 Apr 30;356(6372):791-3.

PMID:
1574117
50.

Supplemental Content

Loading ...
Support Center